Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel

New England Journal of Medicine, 2015

Heidelberg University, Erasmus MC Cancer Institute, University Hospital Heidelberg, Sidney Kimmel Comprehensive Cancer Center, City of Hope, The Netherlands Cancer Institute, University of Perugia, Ruhrlandklinik, University of Duisburg-Essen, Russian Cancer Research Center NN Blokhin, Moffitt Cancer Center, Centrum Onkologii, University of Chicago, Hospital Universitario HM Sanchinarro, Oncology Hematology Care, Duke Medical Center, Massachusetts General Hospital, Centro de Estudios Científicos, Fakultní nemocnice Bulovka, Fondazione IRCCS Istituto Nazionale dei Tumori, Amphia Ziekenhuis, Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario Virgen del Rocío, LungenClinic Grosshansdorf, Bristol-Myers Squibb (United States), Sarah Cannon, Tennessee Oncology

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

8508

Citations

View on Google Scholar

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back